Current options for palliative treatment in patients with pancreatic cancer

Digestive Diseases

Volumn 19, Issue 1, 2001, Pages 63-75

  Ridwelski, Karsten ^a,b   Meyer, Frank ^a  

^a UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

^b City Hospital   (Germany)

Author keywords

Best supportive care; Chemotherapy; Combination therapy; Docetaxel; Gemcitabine; Monotherapy; Pancreatic carcinoma, metastases; Phase I II trials

Indexed keywords

3 [(4,5 DIMETHYL 1H PYRROL 2 YL)METHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; CYTOSTATIC AGENT; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; HORMONE; MARIMASTAT; METHOTREXATE; MITOMYCIN; MITOMYCIN C; OCTREOTIDE; PLATINUM DERIVATIVE; TAMOXIFEN; TANOMASTAT; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; VINCRISTINE;

ADULT; ADVANCED CANCER; AGED; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; CYTOSTASIS; DRUG RESPONSE; DUODENUM OBSTRUCTION; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; JAUNDICE; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; METASTASIS; PAIN; PANCREAS CANCER; PANCREAS CARCINOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SURVIVAL RATE; SYMPTOMATOLOGY;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; DEOXYCYTIDINE; HUMANS; PALLIATIVE CARE; PANCREATIC NEOPLASMS; PROGNOSIS; QUALITY OF LIFE; SURVIVAL ANALYSIS;

EID: 0034988672     PISSN: 02572753     EISSN: None     Source Type: Journal    
DOI: 10.1159/000050655     Document Type: Review

References (70)

1. A phase I trial of MTA and gemcitabine in patients with locally advanced or metastatic cancer
2. Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors
3. Development of a new system for assessing clinical benefit for patients with advanced pancreatic cancer
4. A phase I study of gemcitabine, 5-fluorouracil and leucovorin in patients with advanced, recurrent, and/or metastatic solid tumors
5. Conclusions concerning the symptomatic treatment of cancer of the pancreas
6. The matrix metalloproteinases and their inhibitors in pancreatic cancer. From molecular science to a clinical application
7. Novel non-operative treatment and treatment strategies in pancreatic cancer
8. Phase III evaluation of octreotide versus chemotherapy with 5-fluorouracil or 5-fluorouracil plus leucovorin in advanced exocrine pancreatic cancer: A North Central Cancer Treatment Group study
9. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial
10. Phase II study of gemcitabine in patients with advanced pancreatic cancer
11. A phase I-II study of gemcitabine and docetaxel in advanced pancreatic cancer: A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD)
12. Phase II trial of gemcitabine (2,2′)-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas
13. Phase II-study of gemcitabin and docetaxel in patients with metastatic pancreatic cancer
14. Tumor of the pancreas: Support treatment
15. A dose-finding study of gemcitabine and vinorelbine in advanced previously treated malignancies
16. Phase I evaluation of sequential doxorubicin, gemcitabine then ifosfamide paclitaxel cisplatin for patients with unresectable or metastatic transitional-cell carcinoma of the urothelial tract
17. Cisplatin, gemcitabine, and paclitaxel in locally advanced or metastatic non-small-cell lung cancer: A phase I-II study
18. Cisplatin, gemcitabine and vinorelbine in locally advanced or metastatic non-small-cell lung cancer: A phase I study
19. Radiologic diagnosis and staging of pancreatic ductal adenocarcinoma
20. A phase I-II study of gemcitabine and paclitaxel in advanced non-small-cell lung cancer patients
21. Evaluation of the utility of a radioimmunoassay for serum CA 19-9 levels in patients before and after treatment of carcinoma of the pancreas
22. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer
23. Aktuelle aspekte in der diagnostik und therapie des pankreaskarzinoms
24. Phase I/II trial of paclitaxel by 1-hour infusion, carboplatin, and gemcitabine in the treatment of patients with advanced non-small-cell lung carcinoma
25. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer
26. Clinical nutrition in liver and pancreatic diseases
27. Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer
28. CA 19-9 in evaluating the response to chemotherapy in advanced pancreatic cancer
29. The matrix metalloproteinases and their inhibitors in the treatment of pancreatic cancer
30. A phase I/II study of gemcitabin (G) and docetaxel (D) in patients (Pts) with unresectable pancreatic cancer
31. First-line treatment with docetaxel (D) and gemcitabine (G) in patients with advanced pancreatic cancer: A multicenter phase II study
32. Gemcitabine-cisplatin: A schedule finding study
33. Experimental drugs and drug combinations in pancreatic cancer
34. Phase I/II study of gemcitabine plus vinorelbine as first-line chemotherapy of non-small-cell lung cancer
35. Activity of weekly Taxotere (TXT) in patients with metastatic breast cancer
36. Phase I study of weekly docetaxel (Taxotere) in heavily pre-treated breast cancer patients
37. Chemotherapy in pancreatic cancer: Results of a controlled, prospective, randomised, multicentre trial
38. Problems of antineoplastic chemotherapy of pancreatic cancer
39. Phase I study of the gemcitabine/oxaliplatin combination in patients with advanced solid tumors: A preliminary report
40. Psychosomatic aspects of gastrointestinal disease
41. Activity of gemcitabine in patients with advanced pancreatic carcinoma. A review
42. Gemcitabine: A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer
43. Phase I trial of gemcitabine (Gemzar), 24 h infusion 5-fluorouracil and folinic acid in patients with inoperable pancreatic cancer
44. Chemotherapy prolongs survival in inoperable pancreatic carcinoma
45. Depression in patients with pancreatic carcinoma: Diagnostic and treatment issues
46. Phase I trial of Taxotere: Five-day schedule
47. Phase 3 trial of SMS 201-995 pa LAR vs. placebo in unresectable stage II, III and IV pancreatic cancer
48. Gemcitabine and UFT plus oral calcium folinate: Phase I study
49. A phase I study of gemcitabine and epirubicin for the treatment of platinum-resistant or refractory advanced ovarian cancer
50. Neue Zytostatika: 1. Gemcitabin bei soliden tumoren - Kombinations-partner mit guter verträglichkeit
51. Leucovorin, 5-fluorouracil, and gemcitabine: A phase I study
52. Matrix metalloproteinase inhibition as a novel anticancer strategy: A review with special focus on batimastat and marimastat
53. A phase I trial of gemcitabine and infusional 5-fluorouracil (5-FU) in patients with refractory solid tumors: Louisiana Oncology Associates Protocol No. 1 (LOA-1)
54. A phase I trial of docetaxel and gemcitabine in patients with advanced cancer
55. Docetaxel and gemcitabine combinations in non-small cell lung cancer
56. Marimastat in patients with advanced pancreatic cancer: A dose-finding study
57. A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma
58. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer
59. Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumors
60. Phase II study of Taxotere® (RP56976, docetaxel) in pancreatic adenocarcinoma
61. A phase I study of gemcitabine and docetaxel in patients with metastatic solid tumors
62. Pancreatic carcinoma: Conservative and adjuvant therapy
63. Chemotherapy of adenocarcinoma of the pancreas
64. Phase I study of docetaxel dose escalation in combination with fixed weekly gemcitabine in patients with advanced malignancies
65. An investigational new drug treatment program for patients with gemcitabine: Results for over 3000 patients with pancreatic carcinoma
66. Nonoperative management of pancreatic cancer
67. Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis
68. Activity of high-dose epirubicin combined with gemcitabine in advanced non-small-cell lung cancer: A multicenter phase I and II study
69. Somatostatin analogs in the treatment of pancreatic cancer: Utopia or feasible alternative?